Image Source: scientificamerican.com
Admittedly, some big pharmaceuticals have come under fire for their failure to produce safe drugs. Internationally, damages filed against them have drained the resources of some and put to question their models for producing drugs.
These backlashes have naturally tainted their operations, undermining the strong historical foundations of their operations. Pharmaceuticals were once hailed as indices for the advancement of medical technology.
Image Source: businessclimate.com
This exposé by The New Yorker cleverly runs the reader through the development of pharmaceutical companies to what they are now. With billion-dollar mergers behind them, today’s hyphenated pharmaceutical names are a triumph of forgetting the sophisticated Swiss and German models that launched their relevance. Admittedly, pharmaceuticals that have come under fire for failing to produce relevant drugs have failed to derive success from these models after years of trying to develop them.
The Swiss and German laboratories of yore were at the forefront of assiduous discovery and testing of new compounds that form the basic components of drugs. In theory, they have provided a valiant backbone in the crusade against the multiplication of diseases. These models are expensive to maintain, but fruition could have attenuated the costs. However, The New Yorker also points out that despite such a strong foundation, there is still a want for new, innovative drugs that are not of the “me, too” kind.
Image Source: foxnews.com
Perhaps what’s left for big pharmaceuticals to do is forgo aggressive expansion in favor of getting down to productive research. The world is in desperate need of new, safe drugs to combat the rising statistics of mortality and morbidity from diseases.
The pharmaceutical industry is the subject of many analyses for its continuing improvement. For more insights, consult this Facebook page offering the outlook of Mary Szela, a well-placed executive of Abbott Laboratories.
